Skip to content

Trial Summary

A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ LocallyAdvanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers

Acronym:

EMBER

ACTRN/NCT /ethics:

NCT04188548

Scientific title:

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Sponsor / Cooperative group:

Eli Lilly and Company

Trial & Patient Characteristics

Cancer TypeBreast
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
SexFemale
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2019-12-10
Anticipated End Date2023-04-26

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Meena Okera
Recruitment StatusRecruiting